As­cendis scores FDA ap­proval for hy­poparathy­roidism can­di­date to re­place Takeda's pulled drug

As­cendis Phar­ma an­nounced Mon­day that it won FDA ap­proval for its hy­poparathy­roidism drug, of­fer­ing the small com­mu­ni­ty of those suf­fer­ing from in­suf­fi­cient lev­els of parathy­roid …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER